Navigation Links
Novel Radiation Therapy to Treat Lung Cancer Used for the First Time in United States, at New York Hospital Queens
Date:12/17/2009

FLUSHING, N.Y., Dec. 17 /PRNewswire-USNewswire/ -- A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

"Although the patient came in because of pain in his arm, it was not due to an injury. It was discovered that the cause was a Pancoast tumor, a tumor in the lungs that affects the arms and shoulders but rarely causes symptoms, such as cough or shortness of breath, typically associated with the lungs," according to Dattatreyudu Nori, M.D., chairman, Radiation Oncology.

The patient was treated with high dose chemotherapy and then underwent treatment with external beam radiation. Although he did have some positive response, the tumor was still present. Because of the location of the tumor, the NYHQ physicians knew that additional conventional treatment could endanger surrounding critical structures including nerves and vessels, and could affect the other organs of his body.

With the options becoming limited, Dr. Nori, along with colleague Paul C. Lee, M.D., the hospital's vice chairman of cardiothoracic surgery, decided to perform a surgical resection of the tumor and then implanted the tumor bed with radioactive Cesium 131 pellets -- in a new type of brachytherapy procedure. Brachytherapy involves the implantation of radioactive seeds into the tumor site to kill the remaining cancer cells after surgical resection, while limiting the damage to healthy tissue. Brachytherapy has been successful in treating prostate cancer, but had never been used to treat this form of aggressive lung cancer.

"The tumor was very aggressive. We decided to use radioactive Cesium-131 pellets due to their high success rate in treating prostate cancer. This patient has responded well to the treatment, with an outcome that would not have been possible with traditional treatment," reports Dr. Nori.

According to Dr. Nori, Cesium-131 pellets have several advantages over the older radioactive isotopes including a shorter half-life, which means faster delivery of a radiation dose that allows less time and opportunity for the cancer cells to repopulate.

Dr. Nori has trained several hundred physicians in the U.S. on the use of brachytherapy procedures in the treatment of cancer, and more recently on the use of Cesium-131 in lung cancer treatment. He is renowned in the field of radiation oncology and for pioneering the use of use of radioactive isotopes to treat prostate cancer. He was one of the first to use the radioactive isotopes Iodine-125 and Palladium-103 in 1975 and 1985 as well as Cesium-131, which was approved by the U.S. Food and Drug Administration in 2003 for treating prostate and other cancers.

New York Hospital Queens is a member of the New York-Presbyterian Healthcare System and an affiliate of the Weill Medical College of Cornell University.

Note to Editors: Dr. Nori as well as the (Spanish-speaking) patient and multi-lingual family members is available for interviews, and interviews can be conducted in multiple languages. Dr. Nori is one of the world's leading authorities in the subspecialty of brachytherapy. He was the first physician in the United States to work with a computerized brachytherapy treatment system and was instrumental in the development and successful application of it to combat cancer.

CONTACT: Cynthia Bacon, +1-718-670-2515, Camela Morrissey, +1-718-670-1065, or David Levine, +1-212-772-9447, all of New York Hospital Queens

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dattatreyudu Nori, MD

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=90700

SOURCE New York Hospital Queens


'/>"/>
SOURCE New York Hospital Queens
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
2. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
3. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
4. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
5. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
6. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. Starch Medical Launches Novel Plant Sourced Surgical Hemostatic Pad
10. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
11. Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 ... 2016-2022 Among the various wound care products type, the advanced ... in 2015. Among the various applications, surgical wound segment held the largest ...
(Date:3/24/2017)... SHANGHAI , March 24, 2017 /PRNewswire/ ... organization providing high-quality and cost-effective drug development ... the pharmaceutical and biotechnology industry, announced today ... ShangPharma will be consolidating the ... Organizations (CMO) under Shanghai ChemPartner. These entities ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 ... market of deep learning solutions within the healthcare domain. Primarily driven ... a novel solution to generate relevant insights from medical data. ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy ... be found at 9618 Huebner Road. The clinic is the group’s 7th location in ... and Dr. Ali Higgins, PT, will provide care from the clinic, which opened March ...
(Date:3/24/2017)... ... March 24, 2017 , ... In ... innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 ... – with nearly 2,000 consumers (and counting) already backing the campaign. , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The law firm ... Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the ... for the firm, will concentrate her practice in elder law, Medicaid planning and applications, ...
(Date:3/24/2017)... ... 2017 , ... Judy Buchanan, co-owner of Serenity Natural Health ... says, “I am passionate about sharing Reiki as a holistic, complementary therapy with ... time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical Reiki™ ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... inspiring stories about real people of God in congregations across the United States. ... a Presbyterian minister ordained in 1964 who has served congregations in seven states ...
Breaking Medicine News(10 mins):